Although orexins are present in the CSF at normal concentrations in other hypersomnolence disorders, including IH [12, 15], findings from preclinical and clinical studies suggest that OX2R agonists may be useful for treating populations with primary sleep disorders not associated with orexin deficiency. The gene discussed is HCRTR2; the disease is isolated hemihyperplasia.